SONN
- Sonnet BioTherapeutics Holdings, Inc.
()
Overview
Company Summary
Sonnet BioTherapeutics Holdings, Inc. is a biotechnology company focused on the development and commercialization of innovative immunotherapy platforms for the treatment of cancer and other diseases. They harness the power of biology to create next-generation therapeutic solutions that aim to improve patient outcomes.
Sonnet BioTherapeutics uses proprietary technologies and platforms to develop targeted therapeutic antibodies and biologic drugs. Their approach involves designing and engineering therapeutic candidates that can selectively target specific tumor types or disease areas. By targeting these specific areas, Sonnet aims to increase treatment efficacy while minimizing potential side effects.
One of the company's key platforms is SON-080, a fully human monoclonal antibody, which they are developing as a potential treatment for several types of cancer. SON-080 is designed to specifically target and bind to a tumor-associated antigen present on multiple cancer types. This targeted approach aims to activate the patient's immune system to fight against cancer cells, potentially leading to enhanced clinical responses.
In addition to their lead product, Sonnet BioTherapeutics is also actively exploring collaborations and partnerships with other biopharmaceutical companies and research institutions to leverage their platform technologies and advance the development of innovative therapies.
Overall, Sonnet BioTherapeutics Holdings, Inc. operates in the field of biotechnology, focusing on the development and commercialization of targeted immunotherapy platforms for cancer and other diseases. Their aim is to provide novel treatments that can improve patient outcomes and contribute to the advancement of biomedical research.